The acquisition removes supply-chain risk for SpyGlass's lead BIM-IOL System and adds a revenue-generating licensing business. Monitor Phase 3 trial timelines and FDA interactions for the BIM-IOL System, as well as any updates on premium IOL development.
Price Chart
Executive Summary
SpyGlass Pharma acquires AVS from Santen for ~$13M cash, securing commercial IOL manufacturing capacity for its Phase 3 BIM-IOL System. The deal also provides AVS's glistening-free lens material licensing revenue from Bausch + Lomb and other partners, supporting SpyGlass's strategy to expand into premium IOL options.
Key Financial Metrics
Key Facts
- Acquisition of AVS for ~$13M in cash, a wholly owned subsidiary of Santen and current supplier of SpyGlass's IOL for Phase 3 trials.
- AVS will be exclusive manufacturer/supplier of IOLs to Santen for Japan commercialization; continues licensing glistening-free hydrophobic acrylic lens material to Bausch + Lomb for enVista IOL line.
- Deal secures scalable commercial IOL manufacturing capacity and accelerates pathway to adding premium lens options (toric, extended depth-of-focus) to SpyGlass's drug delivery platform.
- SpyGlass plans to maintain existing cash runway and strategy; no financing details disclosed.
Financial Impact
~$13M cash acquisition; AVS brings ongoing licensing revenue from Bausch + Lomb and manufacturing contracts with Santen and other global IOL companies.
Risk Factors
- Integration and manufacturing scale-up risks for AVS facility.
- Potential delays or cost overruns in commercial IOL production for BIM-IOL System.
- Dependence on continued licensing relationships with Santen and Bausch + Lomb.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372806 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $26.16 $27.71 | ▲ +5.93% | ▲ +5.40% | $29.50 (+12.79%) |
Oct 19, 2026 7d ago | Press Release | $24.60 $26.16 | ▲ +6.34% | ▲ +6.01% | $29.50 (+19.94%) |
Oct 1, 2026 25d ago | 8-K | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.50 (+11.34%) |
Oct 1, 2026 25d ago | Press Release | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.50 (+11.34%) |
May 14, 2026 23w ago | 8-K | $23.21 $22.24 | ▼ −4.18% | ▼ −4.12% | $29.50 (+27.12%) |
Mar 26, 2026 30w ago | Press Release | $22.61 $23.37 | ▲ +3.36% | ▲ +3.72% | $29.50 (+30.50%) |
Mar 9, 2026 33w ago | Press Release | $27.12 $26.82 | ▼ −1.11% | ▼ −0.92% | $29.50 (+8.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers